Table 1.
Participant Entry Characteristics
| Characteristic | Parent Trial | Total DVR |
All Participants | ||
|---|---|---|---|---|---|
| The Ring Study Placebo |
The Ring Study DVR |
DREAM DVR |
|||
| No. of participants enrolled | 48 | 80 | 23 | 103 | 151 |
| Age, y | |||||
| ȃ18–21 | 9 (18.8) | 16 (20.0) | 0 | 16 (15.5) | 25 (16.6) |
| ȃ22–25 | 18 (37.5) | 30 (37.5) | 6 (26.1) | 36 (35.0) | 54 (35.8) |
| ȃ26–30 | 14 (29.2) | 18 (22.5) | 10 (43.5) | 28 (27.2) | 42 (27.8) |
| ȃ31–35 | 2 (4.2) | 9 (11.3) | 5 (21.7) | 14 (13.6) | 16 (10.6) |
| ȃ36 and above | 5 (10.4) | 7 (8.8) | 2 (8.7) | 9 (8.7) | 14 (9.3) |
| Marital status | |||||
| ȃMarried | 3 (6.3) | 4 (5.0) | 1 (4.3) | 5 (4.9) | 8 (5.3) |
| ȃSingle | 44 (91.7) | 75 (93.8) | 21 (91.3) | 96 (93.2) | 140 (92.7) |
| ȃSeparated | 1 (2.1) | 1 (1.3) | 1 (4.3) | 2 (1.9) | 3 (2.0) |
| On ARVsa | 2 (4.2) | 8 (10) | 17 (73.9) | 25 (24.3) | 27 (17.9) |
Data are presented as No. (%). Percentages are expressed as the percentage of the total number of participants enrolled in each treatment group.
Abbreviations: ARV, antiretroviral drug; DREAM, dapivirine ring extended access and monitoring; DVR, dapivirine vaginal ring.
As reported by participant.